Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology operating margin
Operating margin is operating income as a percentage of revenue.
Vir Biotechnology's operating margin for the twelve months ending Sep 30, 2026 was -69.8%. For fiscal 2025 it was -699.2%, against -791.3% the year before. The highest annual figure on record is 51.6% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -699.2% | +92.1 |
| FY2024 | Dec 31, 2024 | -791.3% | +2.8 |
| FY2023 | Dec 31, 2023 | -794.0% | −845.6 |
| FY2022 | Dec 31, 2022 | 51.6% | +13.1 |
| FY2021 | Dec 31, 2021 | 38.4% | +427.3 |
| FY2020 | Dec 31, 2020 | -388.9% | +1810.8 |
| FY2019 | Dec 31, 2019 | -2199.7% | −1087.1 |
| FY2018 | Dec 31, 2018 | -1112.6% | +1896.9 |
| FY2017 | Dec 31, 2017 | -3009.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 30.7% | +4633.2 |
| Q4 FY2025 | Dec 31, 2025 | -74.8% | +871.9 |
| Q3 FY2025 | Sep 30, 2025 | -72267.9% | −62549.3 |
| Q2 FY2025 | Jun 30, 2025 | -9754.3% | −4595.6 |
| Q1 FY2025 | Mar 31, 2025 | -4602.5% | −4460.4 |
| Q4 FY2024 | Dec 31, 2024 | -946.7% | −118.6 |
| Q3 FY2024 | Sep 30, 2024 | -9718.7% | −2642.8 |
| Q2 FY2024 | Jun 30, 2024 | -5158.7% | +508.6 |
| Q1 FY2024 | Mar 31, 2024 | -142.0% | +85.7 |
| Q4 FY2023 | Dec 31, 2023 | -828.1% | −523.5 |
| Q3 FY2023 | Sep 30, 2023 | -7075.9% | −7127.9 |
| Q2 FY2023 | Jun 30, 2023 | -5667.3% | −5749.5 |
| Q1 FY2023 | Mar 31, 2023 | -227.7% | −298.1 |
| Q4 FY2022 | Dec 31, 2022 | -304.6% | −253.1 |
| Q3 FY2022 | Sep 30, 2022 | 52.1% | +17.6 |
| Q1 FY2022 | Mar 31, 2022 | 82.3% | +8110.2 |
| Q4 FY2021 | Dec 31, 2021 | 70.3% | +6322.0 |
| Q3 FY2021 | Sep 30, 2021 | -51.5% | +4492.8 |
| Q2 FY2021 | Jun 30, 2021 | 34.5% | +77.8 |
| Q1 FY2021 | Mar 31, 2021 | -8028.0% | −6770.4 |
| Q4 FY2020 | Dec 31, 2020 | -6251.7% | +254.3 |
| Q3 FY2020 | Sep 30, 2020 | -4544.3% | −1145.9 |
| Q2 FY2020 | Jun 30, 2020 | -43.4% | +1704.0 |
| Q1 FY2020 | Mar 31, 2020 | -1257.6% | −417.1 |
| Q4 FY2019 | Dec 31, 2019 | -6506.0% | −5648.8 |
| Q3 FY2019 | Sep 30, 2019 | -3398.4% | −2207.9 |
| Q2 FY2019 | Jun 30, 2019 | -1747.4% | – |
| Q1 FY2019 | Mar 31, 2019 | -840.5% | – |
| Q4 FY2018 | Dec 31, 2018 | -857.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -1190.5% | – |
See a number that looks wrong?